When was RhoDx founded?

RhoDx was founded in 2016 and raised its 1st funding round 5 years after it was founded.

Where is RhoDx located?

RhoDx is headquartered in St. Louis, United States.

How many employees does RhoDx have?

As of Jun 30, 2026, the latest employee count at RhoDx is 3.

Is RhoDx a funded company?

RhoDx is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on 2021.

When was the latest funding round of RhoDx?

RhoDx's latest funding was a $***** Seed round on 2021, with participation from 1 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $2.9B in funding in 2026 to date.

Where does RhoDx rank among its competitors?

RhoDx ranks 80th amongst 105 active competitors, of which 35 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Lucida Medical, which secured $11.5M in Mar, 2026.

Who are the top competitors of RhoDx?

RhoDx's top competitors include Scholar Rock, SamanTree Medical and Lucida Medical. Among them, Lucida Medical secured the most recent funding round in March, 2026.

RhoDx - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of cell-free DNA-based liquid biopsy for detecting cancer. The company has three technologies NexGenAbler, PointSuppressor, and MethylMarker are non-invasive for cancer screening and monitoring. NexGenAbler method is for quantitative measurement of mutations in cell-free DNA.

Website: www.rhodx.com/
Email ID: *****@rhodx.com

Key Metrics

Founded Year

2016

Location

St. Louis, United States

Stage

Seed

Latest Funding Round

Seed, 2021, $*****

Investors

BioGenerator

Ranked

80^th among 105 active competitors

Employee Count

3 as on Jun 30, 2026

Similar Companies

SamanTree Medical & 102 more

View RhoDx's full profile

RhoDx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
RHODX, INC. CIN: 463566969 , United States, Active	Dec 31, 1999	-	3 (As on Dec 31, 2023)	-

RhoDx has raised funding over 1 round. Its latest funding round was a Seed round on 2021 for $*****. 1 investor participated in its latest round. RhoDx has 1 institutional investor.

Here is the list of recent funding rounds of RhoDx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2021	9739	Seed	7664	1872	4619	2193

Access funding benchmarks and valuations. Sign up today!

View details of RhoDx's funding rounds and investors

The founders of RhoDx is Charlie Rodi.

Here are the details of RhoDx's key team members:

Charlie Rodi: Founder & CEO of RhoDx.
Contact Info: 1 email address

View details of RhoDx's Founder profiles and Board Members

RhoDx's employee count trend

RhoDx has 3 employees as of Jun 26. Here is RhoDx's employee count trend over the years:

Uncover RhoDx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RhoDx include Scholar Rock, SamanTree Medical and Lucida Medical. Here is the list of Top 10 competitors of RhoDx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Scholar Rock 2012, Cambridge (United States), Public	Developer of Antibody-based drugs for the treatment of primary myopathies	$103M	Fidelity Investments, Invus & 10 others	61/100
2nd	SamanTree Medical 2014, Lausanne (Switzerland), Series C	Developer of digital microscopy system for high-resolution imaging of tissue	$57.5M	European Investment Bank, Panakes Partners ... & 13 others	59/100
3rd	Lucida Medical 2019, Cambridge (United Kingdom), Series A	Developer of MRI-based cancer screening technology using artificial intelligence (AI)	$11.5M	prostate-cancer-research.org.uk, IW Capital ... & 20 others	58/100
4th	Sysmex 1968, Kobe (Japan), Public	Developer of diagnostic instruments, reagents, and related software	-	-	55/100
5th	Ionpath 2014, Menlo Park (United States), Series B	Developer of an imaging platform for tissue biopsies	$18M	Samsara BioCapital, Agile Angel & 8 others	53/100
6th	RAYDIAX 2021, Magdeburg (Germany), Series A	Developer of therapy-assist CT system for minimally invasive interventions	$8.4M	Bmp Ventures, HTGF & 4 others	52/100
7th	NeoCura 2017, Changping (China), Series A	Provider of an AI-enabled immunotherapy based tumor diagnostic platform	$38.2M	CDH, PICC Capital Investment Management & 5 others	51/100
8th	Ferronova 2016, Salisbury (Australia), Series A	Provider of magnetic probe based device of treatment of multiple cancer	$17.5M	Uniseed, Renew Pharmaceuticals & 7 others	51/100
9th	Windtree Therapeutics 1992, Philadelphia (United States), Public	Developer of therapies for oncology and cardiovascular diseases with unmet needs	$45K	VMS Asset Management, Panacea Venture & 2 others	51/100
10th	Imagion Biosystems 2016, Albuquerque (United States), Public	Developer of molecular magnetic resonance imaging technology for cancer detection	-	Marbruck Investments, HHS & 1 others	49/100
80th	RhoDx 2016, St. Louis (United States), Seed	Developer of cell-free DNA-based liquid biopsy for detecting cancer	-	BioGenerator	22/100